BibTex RIS Cite

Nadir Bir Genetik Hastalık: Pakionişya Konjenita Tip 2

Year 2013, Volume: 7 Issue: 4, 193 - 195, 01.12.2013

Abstract

Pakionişi konjenita (PK), nadir görülen kalıtsal ektodermal hastalık olup temel olarak hipertrofik tırnak distrofisi ve fokal palmoplantar keratoderma ile karakterizedir. Hastalık PK-1 ve PK-2 şeklinde keratin genindeki mutasyonlarla korelasyon gösteren iki klinik alt gruba ayrılmaktadır. Her ne kadar her iki grubun en belirgin klinik özelliği hipertrofik tırnak distrofisi olsa da, oral lökokeratozis genellikle PK-1’de görülürken, PK-2 ise sıklıkla tırnak distrofisi, yaygın steatosistoma, natal diş ve saç anomalileri ile prezente olur. Burada PK-2’nin klasik bulguları ile prezente olmuş ve ailesinde dört kuşağı etkilenmiş olan bir olgu sunulmuştur.

References

  • Smith F. The molecular genetics of keratin disorders. Am J Clin Dermatol 2003;4:347-64.
  • leachman SA, Kaspar Rl, Fleckman P, Florell SR, Smith FJ, Mclean WH, et al. Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc 2005;10:3-17.
  • Smith FJ, liao H, Cassidy AJ, Stewart A, Hamill KJ, Wood P, et al. The genetic basis of pachyonychia congenita. J Investig Dermatol Symp Proc 2005;10:21-30.
  • Jadassohn J lF. Pachyonychia congenita. Keratosis Disseminata Circumscripta (follicularis). Tylomata. In: neisser A (ed). leuko- keratosis linguae, in Ikonographia Dermatologica. J.E.e., Berlin: urban & Schwarzenberg, 1906:29-31.
  • Jackson AD, lawler SD. Pachyonychia congenita; A report of six cases in one family, with a note on linkage data. Ann Eugen 1951;16:142-46.
  • Kökçam i, uyar B. Bir Pakionişi Konjenita olgusu. T Klin Dermatoloji 1998:8:106-9.
  • Hannaford RS, Stapleton K. Pachyonychia congenita tarda. Australas J Dermatol 2000;41:175-7.
  • Xiao SX, Feng YG, Ren XR, Tan SS, li l, Wang JM, et al. A novel mutation in the second half of the keratin 17 1A domain in a large pedigree with delayed-onset pachyonychia congenita type 2. J Invest Dermatol 2004;122:892-5.
  • Smith FJ, Hansen CD, Hull PR, leachman SA, Kaspar Rl, Schwartz ME, et al. Pachyonychia Congenita. Gene Reviews. [cited 26 July, 2012; Available from: http://www.ncbi.nlm.nih.gov/ books/nBK1280/.
  • Scholz IM, Helmbold P. Pachyonychia congenita type 2. J Dtsch Dermatol Ges 2011;9:144-45.
  • Connors JB, Rahil AK, Smith FJ, Mclean WH, Milstone lM. Delayed-onset pachyonychia congenita associated with a novel mutation in the central 2B domain of keratin 16. Br J Dermatol 2001;144:1058-62.
  • Vaccaro M, Guarneri F, Barbuzza O, Guarneri C. Pachyonychia congenita tarda affecting only the nails. Dermatol Online J 2008;14:12.
  • Milstone lM, Fleckman P, leachman SA, leigh IM, Paller AS, van Steensel MA, et al. Treatment of pachyonychia congenita. J Investig Dermatol Symp Proc 2005;10:18-20.
  • Hickerson RP, Smith FJ, Reeves RE, Contag CH, leake D, leachman SA, et al. Single-nucleotide-specific siRnA targeting in a dominant negative skin model. J Invest Dermatol 2008;128:594- 605.
  • Hickerson RP, leake D, Pho lH, leachman SA, Kaspar Rl. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci 2009;56:82-8.
  • Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol 2006;154: 763-65.

A Rare Genetic Disease: Pachyonychia Congenita Type 2

Year 2013, Volume: 7 Issue: 4, 193 - 195, 01.12.2013

Abstract

Pachyonychia congenita (PC) is a rare inherited ectodermal disorder characterized mainly by hypertrophic nail dystrophy and focal palmoplantar keratoderma. Pachyonychia congenita can be divided into two main clinical subtypes, PC-1 and PC-2, which are correlated with mutations in keratins. Although the most prominent clinical feature of both PC subtypes is hypertrophic nail dystrophy, oral leukokeratosis is usually seen in PC-1 while PC-2 generally presents with nail dystrophy, widespread steatocystomas, natal teeth and hair abnormalities. We report a patient with PC type II presenting with the classical features of the disease that had been transmitted for four generations

References

  • Smith F. The molecular genetics of keratin disorders. Am J Clin Dermatol 2003;4:347-64.
  • leachman SA, Kaspar Rl, Fleckman P, Florell SR, Smith FJ, Mclean WH, et al. Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc 2005;10:3-17.
  • Smith FJ, liao H, Cassidy AJ, Stewart A, Hamill KJ, Wood P, et al. The genetic basis of pachyonychia congenita. J Investig Dermatol Symp Proc 2005;10:21-30.
  • Jadassohn J lF. Pachyonychia congenita. Keratosis Disseminata Circumscripta (follicularis). Tylomata. In: neisser A (ed). leuko- keratosis linguae, in Ikonographia Dermatologica. J.E.e., Berlin: urban & Schwarzenberg, 1906:29-31.
  • Jackson AD, lawler SD. Pachyonychia congenita; A report of six cases in one family, with a note on linkage data. Ann Eugen 1951;16:142-46.
  • Kökçam i, uyar B. Bir Pakionişi Konjenita olgusu. T Klin Dermatoloji 1998:8:106-9.
  • Hannaford RS, Stapleton K. Pachyonychia congenita tarda. Australas J Dermatol 2000;41:175-7.
  • Xiao SX, Feng YG, Ren XR, Tan SS, li l, Wang JM, et al. A novel mutation in the second half of the keratin 17 1A domain in a large pedigree with delayed-onset pachyonychia congenita type 2. J Invest Dermatol 2004;122:892-5.
  • Smith FJ, Hansen CD, Hull PR, leachman SA, Kaspar Rl, Schwartz ME, et al. Pachyonychia Congenita. Gene Reviews. [cited 26 July, 2012; Available from: http://www.ncbi.nlm.nih.gov/ books/nBK1280/.
  • Scholz IM, Helmbold P. Pachyonychia congenita type 2. J Dtsch Dermatol Ges 2011;9:144-45.
  • Connors JB, Rahil AK, Smith FJ, Mclean WH, Milstone lM. Delayed-onset pachyonychia congenita associated with a novel mutation in the central 2B domain of keratin 16. Br J Dermatol 2001;144:1058-62.
  • Vaccaro M, Guarneri F, Barbuzza O, Guarneri C. Pachyonychia congenita tarda affecting only the nails. Dermatol Online J 2008;14:12.
  • Milstone lM, Fleckman P, leachman SA, leigh IM, Paller AS, van Steensel MA, et al. Treatment of pachyonychia congenita. J Investig Dermatol Symp Proc 2005;10:18-20.
  • Hickerson RP, Smith FJ, Reeves RE, Contag CH, leake D, leachman SA, et al. Single-nucleotide-specific siRnA targeting in a dominant negative skin model. J Invest Dermatol 2008;128:594- 605.
  • Hickerson RP, leake D, Pho lH, leachman SA, Kaspar Rl. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci 2009;56:82-8.
  • Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol 2006;154: 763-65.
There are 16 citations in total.

Details

Other ID JA94NR23PR
Journal Section Case Report
Authors

Dilek Azkur This is me

Mustafa Erkoçoğlu This is me

Ersoy Civelek This is me

Gülen Eda Ünite This is me

Can Naci Kocabaş This is me

Publication Date December 1, 2013
Submission Date December 1, 2013
Published in Issue Year 2013 Volume: 7 Issue: 4

Cite

Vancouver Azkur D, Erkoçoğlu M, Civelek E, Ünite GE, Kocabaş CN. A Rare Genetic Disease: Pachyonychia Congenita Type 2. Türkiye Çocuk Hast Derg. 2013;7(4):193-5.


The publication language of Turkish Journal of Pediatric Disease is English.


Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 10 original articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.


The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.